Integra Lifesciences Holdings Corp (IART) Stock Price & Analysis
Integra Lifesciences Holdings Corp (IART) rose 5.67% to USD 17.9 as of June 10, 2026 at 03:32 UTC, according to Nexqual real-time market data.
IART last closed at USD 16.94; the session ranged USD 17.08–18.05 on volume of 775,532 shares. Market capitalization is $1.39B, with a 52-week range of USD 8.7–18.05 (NMS). Source: Nexqual, June 10, 2026 at 03:32 UTC.
Key Statistics (as of June 10, 2026 at 03:32 UTC)
| Price | USD 17.9 |
|---|---|
| Change | ▲ 5.67% (up) |
| Previous Close | USD 16.94 |
| Open | USD 17.2 |
| Day Range | USD 17.08 – 18.05 |
| 52-Week Range | USD 8.7 – 18.05 |
| Volume | 775,532 shares |
| Market Cap | $1.39B |
| Exchange | NMS |
Technical Analysis (IART)
Nexqual's technical model rates IART "BUY" based on 5 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 03:32 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 73.52 (overbought) |
| vs SMA50 | Above (USD 12.73) |
| MACD | 1.29 (positive) |
Analyst Ratings (IART)
Wall Street analysts rate IART "Hold" based on 7 analysts, with a mean price target of USD 17.43 (range USD 11–27), per Nexqual as of June 10, 2026 at 03:32 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 17.43 |
| High Target | USD 27 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 2 / 6 / 2 |
Earnings (IART)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 0.48 |
| Revenue Estimate | $417.62M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.54 vs est 0.4 ▲ beat |
| 2025-12-31 | USD 0.83 vs est 0.8 ▲ beat |
| 2025-09-30 | USD 0.54 vs est 0.43 ▲ beat |
| 2025-06-30 | USD 0.45 vs est 0.43 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
Financials & Fundamentals (IART)
| Total Revenue | $1.64B |
|---|---|
| Revenue Growth (YoY) | +2.40% |
| Gross Margin | +56.72% |
| Operating Margin | +10.41% |
| Profit Margin | -30.15% |
| ROE | -38.63% |
| Debt / Equity | 195.79 |
| Current Ratio | 3.38 |
| Total Cash | $265.50M |
| Total Debt | $2.04B |
| Free Cash Flow | $69.29M |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
Financial Health Score (IART)
Nexqual rates Integra Lifesciences Holdings Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:32 UTC.
| Growth | Mixed — Revenue +1.5% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 10% |
| Balance Sheet | Weak — $266M cash vs $2.04B debt |
| Cash Flow | Mixed — FCF $69M, slim 4.2% margin |
| Efficiency | Critical — ROE -39%, ROA 2.5% |
Ownership (IART)
| Insider Ownership | +14.30% |
|---|---|
| Institutional Ownership | +101.12% |
| Shares Outstanding | 77.80M |
| Float | 58.69M |
| Short % of Float | +14.15% |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
Leadership (IART)
Integra Lifesciences Holdings Corp is led by Stuart M. Essig (age 63), CEO, President & Chairman, per Nexqual as of June 10, 2026 at 03:32 UTC.
| CEO, President & Chairman | Stuart M. Essig (age 63) |
|---|---|
| Executive VP & CFO | Lea Daniels Knight (age 53) |
| Executive VP & President of Tissue Technologies | Robert T. Davis (age 66) |
| Executive VP & President of International Business | Harvinder Pal Singh (age 59) |
| Corporate VP & Chief Technology Officer | Teshtar Elavia |
Major Backers & Investors (IART)
Notable institutional backers of Integra Lifesciences Holdings Corp include Rubric Capital Management LP, Paradigm Capital Management, Morgan Stanley, according to Nexqual as of June 10, 2026 at 03:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rubric Capital Management LP | 9.97% |
| Paradigm Capital Management | 5.16% |
| Morgan Stanley | 4.61% |
| Fuller & Thaler Asset Management Inc. | 4.54% |
| Invesco | 4.48% |
| AIM Sector Funds (Invesco Sector Funds)-INVESCO SMALL CAP VALUE FUND | 4.02% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 3.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 20.55% |
| Vanguard Group | 14.34% |
| State Street | 3.71% |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
From Integra Lifesciences Holdings Corp's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
- It operates through Codman Specialty Surgical and Tissue Technologies segments.
- The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
- It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ICUI | ICU Medical, Inc. | USD 142 | ▲ 3.95% |
| CNMD | CONMED Corporation | USD 36.9 | ▲ 4.95% |
| HAE | Haemonetics Corporation | USD 78.71 | ▲ 10.42% |
| MMSI | Merit Medical Systems, Inc. | USD 67.51 | ▲ 4.7% |
| OFIX | Orthofix Medical Inc. | USD 9.87 | ▼ 4.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:32 UTC. This page is informational and not investment advice.